China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn's disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones. In addition, the company offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis; Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins; Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata; skin heling soothing product; and Hirudoid for acne-prone skin care, prevention, and enhancement of acne. Further, it provides Vmonalisa, modified sodium hyaluronate filler for mid to deep dermal implantation; augentropfen stulln mono eye drops for asthenopia; EyeOP1 glaucoma treatment device; and Elcitonin for Osteoporosis pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.